Peel Hunt restated their hold rating on shares of Horizon Discovery Group (LON:HZD) in a research note issued to investors on Thursday.
Separately, Numis Securities reaffirmed a buy rating on shares of Horizon Discovery Group in a research note on Monday, September 17th.
Shares of HZD opened at GBX 179 ($2.34) on Thursday. Horizon Discovery Group has a 52-week low of GBX 160 ($2.09) and a 52-week high of GBX 294 ($3.84).
About Horizon Discovery Group
Horizon Discovery Group plc, an integrated life science company, designs, manufactures, and applies gene editing and gene modulation to build cell models that harbour the genetics of human disease in the Americas, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Products, Services, and Leveraged Research and Development (R&D) segments.
Featured Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for Horizon Discovery Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group and related companies with MarketBeat.com's FREE daily email newsletter.